Efficacy of a Dexamethasone-Eluting Nitinol Stent on the Inhibition of Pseudointimal Hyperplasia in a Transjugular Intrahepatic Portosystemic Shunt: An Experimental Study in a Swine Model by Seo, Tae-Seok et al.
Korean J Radiol 6(4), December 2005 241
Efficacy of a Dexamethasone-Eluting Nitinol
Stent on the Inhibition of Pseudointimal
Hyperplasia in a Transjugular Intrahepatic
Portosystemic Shunt: An Experimental
Study in a Swine Model
Objective: We wanted to evaluate the feasibility and efficacy of using a dexam-
ethasone (DM)-eluting nitinol stent to inhibit the pseudointimal hyperplasia follow-
ing stent placement in the transjugular intrahepatic portosystemic shunt tract
(TIPS) of a swine.
Materials and Methods: Fifteen stents were constructed using 0.15 mm-thick
nitinol wire; they were 60 mm in length and 10 mm in diameter. The metallic
stents were then classified into three types; type 1 and 2 was coated with the mix-
ture of 12% and 20%, respectively, of DM solution and polyurethane (PU), while
type 3 was a bare stent that was used for control study. In fifteen swine, each
type of stent was implanted in the TIPS tract of 5 swine, and each animal was
sacrificed 2 weeks after TIPS creation. The proliferation of the pseudointima was
evaluated both on follow-up portogram and pathologic examination.
Results: One TIPS case, using the type 1 stent, and two TIPS cases, using the
type 2 stent, maintained their luminal patency while the others were all occluded.
On the histopathologic analysis, the mean of the maximum pseudointimal hyperpla-
sia was expressed as the percentage of the stent radius that was patent, and these
values were 51.2%, 50% and 76% for the type 1, 2, and 3 stents, respectively.
Conclusion: The DM-eluting stent showed a tendency to reduce the develop-
ment of pseudointimal hyperplasia in the TIPS tract of a swine model with
induced-portal hypertension.
ransjugular intrahepatic portosystemic shunt (TIPS) is an effective and
commonly used method for not only lowering portal pressure, but also
for controlling acute variceal bleeding that is retractable to standard
medical treatment for the patients with portal hypertension. However, the one-year
primary patency rates after TIPS creation are 23 50%, and the long-term patency of
TIPS has been disappointing because the rate for the late parenchymal tract abnormal-
ities such as restenosis and occlusion was 75%, and the cumulative patency rate was
5% at 2 years (1 3). TIPS is often associated with the development of pseudointimal
hyperplasia within the stented lumen of the hepatic parenchymal tract.
Restenosis after stent implantation is also one of the problems in vessels, and it is
mainly characterized by an inflammatory response to procedural injury and an intense
fibrocellular response (4). To overcome this problem, drug-eluting stents with anti-
inflammatory and immunosuppressive effects have been developed, and their clinical
applications have been tried in such vessels as the coronary artery. Some studies have
recently reported that the dexamethasone (DM)-eluting stent was effective to reduce
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Tin the unstable angina pectoris patients who underwent
placement of DM-eluting stents compared to the stable
patients (26.86% +/ 14 vs. 38.40% +/ 16%, respec-
tively p < 0.02) (5, 6).
However, the implantation of drug-eluting stent for local
drug delivery in TIPS has not been reported on in the
medical literature. We hypothesized that the DM released
from a DM-eluting stent would inhibit pseudointimal
hyperplasia in the TIPS tract and improve vessel patency.
We made the DM-eluting nitinol stents and we performed
an experimental study with using them in a swine model.
The purpose of this study was to evaluate the feasibility
and efficacy of the DM-eluting nitinol stent for reducing
the pseudointimal hyperplasia in the TIPS tract of a swine
model with induced-portal hypertension.
MATERIALS AND METHODS
Stent Construction
We constructed both the stents and the introducer set in
our research laboratory. The metallic stent was knitted
from a single thread of 0.15 mm nitinol wire filament
(Euroflex, Germany) into a tubular configuration and in an
interlocking diamond-shaped pattern with 6 bent points on
the upper and lower end portions. All the stents were 10
mm in diameter and 60 mm in length when they were fully
expanded.
The DM-eluting stent was made by dipping a metallic
stent in a solution of DM and polyurethane (PU). The
metallic stents were classified into three types. Type 1 and
2 stents were coated with 12% and 20%, respectively, of
the DM solution mixed with PU, while the type 3 stent
was a bare nitinol stent that was used for the control study.
In-vitro Evaluation of the DM Released from the DM-
PU Membrane
To evaluate the amount of DM that was released from
the membrane of the DM/PU mixture that included 12%
DM, a stent with a 1 cm
2 membrane was soaked in a tube
with 0.1 M neutral phosphate buffer solution, and the
bottle was placed in a shaking incubator. The temperature
of the incubator was set to 37 , and the bottle was contin-
uously rotated. The buffer solution was exchanged every
24 hours, and the amount of DM in the buffer solution was
measured by performing high performance liquid
chromatography (Rainin Instrument Co., Wolburn, MA) at
one month. The wavelength to detect the DM was 254 nm,
which was the peak absorption point of DM on the prelim-
inary test.
Animal Experiments
Transjugular Intrahepatic Portosystemic Shunt 
All the experimental procedures were performed under
the National Institute of Health guidelines for the humane
handling of animals and our study was approved by the
committee for animal research at our institution.
Transjugular intrahepatic portosystemic shunt was
performed in 15 domestic pigs that had an initial weight of
15 20 kg each. The authors performed the procedure by
using the techniques described in the previous reports (7,
8). Anesthesia was induced in each swine with an
intramuscular injection of ketamine hydrochloride (Yuhan
Corporation, Seoul, Korea), and the anesthesia was
maintained by intravenous injections whenever needed.
Under fluoroscopic guidance, the right internal jugular vein
was cannulated while iodinated contrast material was
injected through the ear vein, and a 0.035-inch guide wire
(Radiofocus, Terumo, Tokyo, Japan) was then inserted.
The tract was gradually dilated up to 9 Fr with a dilator
and a 9-F Teflon sheath (Transjugular Liver Access Set;
Cook, Bloomington, IN) was coaxially loaded over the
guide-wire and advanced caudally over the guide wire into
the inferior vena cava and hepatic vein. The right hepatic
vein was selected for using a 5 Fr cobra catheter (Cook),
and a hepatic venogram and wedge portogram were taken
for visualization of the portal vein. For the puncture, a
sheathed 16-gauge Colapinto needle (Cook) was placed
into the right hepatic vein, and the portal vein was
punctured via the intrahepatic route. After the confirma-
tion of the portal vein by the aspiration of venous blood
and the injection of contrast media, a guide wire was
advanced into the portal vein and the needle was
removed. After the advancement of a 5 Fr Cobra catheter
into the portal vein, a direct portogram was taken and the
portal pressure was measured (Fig. 1A). To induce portal
hypertension, a microcatheter (Progreat, Terumo, Tokyo,
Japan) was inserted into the portal vein through a cobra
catheter, and an intraportal injection of a mixture of N-
butyl-2-cyanoacrylate and lipiodol (1:3) was done. When
the migration of the mixture from the catheter tip to the
peripheral portion of the portal vein was sluggish, injection
of the mixture was stopped; the total amount of the
mixture was approximately 1 2 ml. After embolization of
the portal vein, the occluded portal perfusion on the
follow-up portogram was confirmed, as well as confirming
the increased portal pressure (Fig. 1B). The parenchymal
tract was dilated with a balloon catheter (10 mm in
diameter, 4 cm in length), and a nitinol stent was placed in
the tract. The final portogram was taken and the portal
pressure was again measured (Fig. 1C). Each type of stent
was implanted in the TIPS tract of 5 swine.
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After two weeks, the animals were sedated with the
same method that was used in the TIPS procedure. To
obtain the follow-up shunt venogram, the portal vein was
selected by the same method as was used in the TIPS
procedure for the swine with a patent tract (Fig. 2A).
Meanwhile, in the swine with the completely occluded
TIPS tract, a direct portogram was taken by the following
method after performing hepatic venogram. The skin of
abdomen was incised about 10 to 15 cm in length at the
midline from the epigastrium. After exposing the small
bowel, the tributary of the superior mesenteric vein was
punctured and the direct portogram was taken each second
after the hand injection of 10 ml of contrast media (Fig.
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Fig. 2. Follow-up portograms taken two
weeks after transjugular intrahepatic
portosystemic shunt.
A. Portogram performed via the hepatic
vein in the DM-releasing stent group
shows a partial focal stenosis.
B. Direct portogram by puncture of a
tributary of the superior mesenteric vein
shows the complete occlusion in the
control group.
AB
Fig. 1. Portograms during stent placement.
A. Under the fluoroscopic guidance, the portal vein was punctured via the right jugular vein, and the portogram was obtained.
B. Portogram that was obtained after inducing portal hypertension by an injection of a mixture of N-butyl-2-cyanoacrylate and lipiodol in
the portal vein, and it shows the occlusion of the portal vein.
C. Portogram taken after the placement of a stent in the transjugular intrahepatic portosystemic shunt tract shows the good flow to the
hepatic vein.2B). Each animal was sacrificed with an intravenous
injection of sodium pentobarbital solution (Hanlim Pharm.
CO., LTD, Seoul, Korea) for the histologic analysis of the
tissue around the TIPS. The liver, the supra-hepatic and
infra-hepatic inferior vena cava and the extrahepatic portal
vein were excised en bloc. The cross sections of the TIPS
tract were obtained, and the specimens were evaluated by
staining with hematoxin-eosin and Masson-trichrome. The
maximal distance of the pseudointimal hyperplasia from
the stent was measured for each animal on the histopatho-
logic examination. The degree of the maximal pseudointi-
mal hyperplasia was calculated by dividing the stent radius
by the thickness of the pseudointimal hyperplasia without
inclusion of any thrombus (Fig. 3).
RESULTS
In-vitro Evaluation of DM Released from the Stent
The mean increased weight of the stent coated with the
DM and PU mixture was 22.3 mg and 25.1 mg for the type
1 and 2 stents, respectively. The mean weight of the DM,
as calculated from the concentration of DM in the solution
of the DM and PU mixture, was 2.7 mg and 5.0 mg for the
type 1 and 2 stents, respectively.
The in-vitro examination using high performance liquid
chromatography showed that the amount of DM released
for the first from the membrane of the DM/PU mixture
was 25% of the loaded dose. The accumulated amounts of
the released DM for the first three days and two weeks
were 50% and 70%, respectively. The total amount of
released DM at one month was 80% (Fig. 4).
Animal Experiments
Transjugular Intrahepatic Portosystemic Shunt 
Transjugular intrahepatic portosystemic shunt
procedures were technically successful in all the swine; all
the stents were deployed accurately without any complica-
tion in all the swine. Although the stents partially
expanded in the intraparenchymal portion of all swine, an
additional balloon dilation was not done because the blood
flow to the hepatic vein was improved without distur-
bance, and the portal pressure was decreased below the
initial pressure.
The mean pressure in the portal vein was 23.44 cmH2O
and 37.94 cmH2O before and after the injection of N-
butyl-2-cyanoacrylate, respectively, and then this immedi-
ately dropped back to 19.72 cmH2O following TIPS.
Follow-up and Sacrifice
On the follow-up portogram taken two weeks after the
stent placement, one case of the 5 swine with the type 1
stent and two cases of the 5 swine with the type 2 stent
displayed luminal patency despite of the focal narrowing of
the lumen in the intraparenchymal portion (Fig. 2A). The
remaining cases using type 1 and 2 stents and all the cases
of the 5 swine with the type 3 stent showed completely
occluded lumens of their stents (Fig. 2B).
Histopathologic Analysis
On the histopathologic analysis, the mean of the
maximal pseudointimal hyperplasia were 51.2%, 50% and
76% for the type 1, 2, and 3 stents. The microscopic
findings showed a relatively thin and uniform pseudointi-
mal hyperplasia within the patent TIPS tract in the type 1
and 2 stents, and there was complete occlusion of the TIPS
tract by pseuointimal hyperplasia in the type 3 stent (Figs.
5A, B). The psuedointimal hyperplasia consisted of
myofibroblasts and an extracellular matrix that had grown
through the stent wires, and inflammatory cells had
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Fig. 3. Calculation of the degree (D) of the maximal pseudoinimal
hyperplasia.
Fig. 4. In-vitro evaluation of the dexamethasone released from a
membrane made from a 12% dexamethasone concentration in a
dexamethasone-polyurethane solution.infiltrated around the stent wires.
DISCUSSION 
Although TIPS is an effective method for reducing the
portal venous pressure in the patient with variceal bleeding
or intractable ascietes due to portal hypertension, a high
rate of restenosis and occlusion of the tract are the critical
drawbacks of this technique (1 3). The important
mechanisms of restenosis or occlusion of the shunt, as
reported in the previous reports, were acute thrombosis,
chronic inflammatory reaction, pseudointimal hyperplasia
and inhibition of the endothelialization process associated
with bile duct injury and bile extravasation within the
stented lumen of the hepatic parenchymal tract (9 12). The
layers of pseudointimal hyperplasia consist of mesenchymal
cells and collagen, and this is covered by a layer endothelial
cells. Various techniques and prosthesis were developed to
reduce the rate of restenosis and to increase primary
patency. Some experimental studies that have used stent-
grafts covered with polyethylene terephthalate, polytetra-
fluoroethylene, dacron, silicone or polycarbonate urethane
were performed in the TIPS tract (13 17). However, the
placement of a stent-graft in the TIPS tract did not prevent
the pseudointimal hyperplasia and it only provided patency
equal to that of the bare stent due to the stent’s early
occlusion or because of late shunt malfunction in selected
cases. Lessie et al. reported on intraluminal irradiation for
TIPS stenosis in a swine model, but the irradiation of the
TIPS did not significantly improve patency or reduce the
degree of pseudointimal hyperplasia (18).
Many investigations have been performed to prevent
restenosis after stent implantation in the vessel. To reduce
the rate of restenosis that’s due to an inflammatory
response to procedural injury and then the intense fibrocel-
lular response, drug-eluting stents with anti-inflammatory
and immunosuppressive effects have been developed and
clinical applications have been tried in various vessels; DM
is one of the drugs that has been used. DM is a glucocor-
ticoid with potent anti-inflammatory, anti-fibrotic, anti-
thrombotic and anti-proliferative properties, and it
interferes with macrophages and reduces the level of
growth factors and cytokines. In vessels, the DM acts to
prevent both adherence and aggregation of granulocytes to
the endothelial cells, and the intimal hyperplasia mediated
by the leukocytes is suppressed (19). DM demonstrated the
ability to suppress myointimal hyperplasia in an in vitro
experiment using a culture of smooth muscle cell (20 22).
However, previous clinical studies have reported that
systemic intravenous, intramuscular or peroral administra-
tions of corticosteroids were not effective treatments for
reducing the restenosis after percutaneous transluminal
angioplasty (23, 24). As for the results of using DM-eluting
stents for placement in vessels, some reports have
suggested the beneficial effects of DM-eluting stents on the
migration and proliferation of the smooth muscle cells of
the vessels, and other reports have suggested that DM-
eluting stent could not reduce neointimal thickening and
thrombotic occlusion within a stent (5, 6, 25 27). Strecker
et al have reported that DM-coated stents reduced the
neointimal hyperplasia in the femoral arteries of dogs (25).
Yoon et al. performed the experiment with placement of a
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Fig. 5. Microcopic specimen ( 10) stained with H-E in a dexamethasone-releasing stent.
A. Microscopic section in the dexamethasone-releasing stent group shows a relatively thin and uniform pseudointimal hyperplasia in the
patent transjugular intrahepatic portosystemic shunt tract.
B. Microscopic section from the control stent group shows the marked ingrowth of fibrotic tissue within the lumen of the stent and
complete occlusion of the transjugular intrahepatic portosystemic shunt tract.
ABDM-coated stent in the canine aorta and inferior vena
cava, and they reported that the stent was effective for
decreasing the neointimal formation. Yoon and coworkers
proved the effectiveness of DM-eluting stent in veins (27).
Contrary to obtaining positive results, Lincoff et al. and
Muller et al. reported their negative results of placing DM-
eluting stent in vessels. In those reports, the DM-eluting
stent was well tolerated within the coronary vessel, but
local delivery of DM by the intravascular DM-eluting stent
did not decrease the neoinitmal hyperplasia in porcine
coronary and carotid arteries (5, 26).
In this study, DM was effective to inhibit the pseudointi-
mal hyperplasia in the TIPS tract. Contrary to histopatho-
logic finding of the control stent, i.e., complete occlusion of
the TIPS tract by being filled with numerous spindle-
shaped myofibroblasts and a collagen matrix, both types of
DM-eluting stents having 12% and 20% DM concentra-
tions suppressed the pseuointimal hyperplasia. The findings
of a thinner pseudointimal layer than the control stent and
the relatively uniform pattern of pseudointimal hyperplasia
in DM-eluting stents may be due to the effects of the DM.
We suspected that DM-eluting stent in the TIPS tract had a
mechanism similar to that seen for the inhibition of
myointimal hyperplasia in the arteries with DM eluting
stents (10). However, despite the inhibition of the psedoin-
timal hyperplasia by the DM, the occlusion of TIPS did
occur, and the vessel patency was not prolonged in the
TIPS with using the DM-eluting stents. These results
suggested that the anti-proliferative effect of DM, which
was eluded from stent alone, was sufficient to reduce
pseudointimal hyperplasia in the TIPS tract, but many
other factors might have also promoted the stenosis and
occlusion of the TIPS tract. In this study, the formation of
thrombus in the TIPS tract was observed on examination
of the gross specimen, and we believed that thrombosis
was an important factor for the high rate of TIPS occlusion
in the swine model with using the DM-eluting stent. The
thrombosis we saw in the TIPS was also suggested to be an
important cause of occlusion in the swine model using
intraluminal irradiation for TIPS stenosis because the
difference between the patent and occluded TIPS was the
presence and/or absence of thrombus within the lumen
(18). Although there are some controversies, the transec-
tion of major bile ducts that occurs during the formation of
the TIPS tract and the leakage of bile from the injured
ducts are both related to the thrombosis observed in the
TIPS tract, and especially for the rapid and early thrombo-
sis (10, 14, 28, 29). The proliferation of the bile duct within
the tissue lined stenotic portion of the TIPS and the
incorporation of bile within thrombi are evidence for the
relation between bile leakage and thrombosis in the TIPS
tract. Although the relationship between thrombosis and
bile leakage was not proven in this experiment, we suggest
that the thrombogenic effect was too strong to be
suppressed by the anti-thrombotic effect of the DM
released from the DM-eluting stents, and the drug effect
was insufficient to prevent thrombosis within the TIPS
tract. Any difference of the anti-thrombotic effect between
the 12% and 20% DM-eluting stents was not observed
because complete occlusions on the follow-up portograms
were noted in both types of stents. However, further
studies are needed to investigate whether the combined
use of anti-thrombotic agents can reduce thrombosis and
solve this problem, and so improve the patency rate for the
TIPS procedure.
The concentration of DM in solution was decided upon
based on results of our preliminary study with taking into
consideration the physical properties of the stent and the
solution. The highest concentration of DM that was achiev-
able in solution for coating without changing the physical
properties of the nitinol stent was 12%, and the radial
force of the stent coated by the solution with a higher
concentration of DM showed a decrease in strength. The
highest possible concentration for coating the stent was
20% because of the viscosity of the solution. Although
Yoon et al reported coating the nitinol stents with 25%
DM-PU solution, twenty percentage was the highest
concentration we could do with our method of coating
(27). Since there was no significant difference in the
thickness of pseudointimal hyperplasia and anti-thrombotic
effect between the 12% and 20% DM eluting stents, the
placement of a 12% DM stent is recommended rather than
placement of a 20% DM stent to inhibit pseudointimal
hyperplasia in the TIPS tract. When comparing both types
of stents, the 20% DM stent will not provide any benefit
over the 12% DM stent for the preservation of the
physical properties of the nitinol stent since the increased
viscosity of the 20% DM solution makes coating the stent
extremely difficult. The 20% DN stent will merely increase
the concentration of DM in the serum.
The reason why the animals were followed-up for only
for two weeks after the creation of TIPS was that in the
swine model, all the TIPS tracts were occluded after two
week. Although swine models are widely used because
TIPS can be performed with the same techniques and
devices used in human and the healing responses after
surgery are similar to those of human, the animals rapidly
increase in weight and size, and they can be difficult to
handle. In another study, stenosis and occlusion progressed
within 2 4 weeks of TIPS formation in swine (14). In this
study, all the TIPS tracts with using the control stent were
completely occluded by myofibroblasts, extracellular
Seo et al.
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TIPS; so, a two week follow-up period might be sufficient.
In conclusion, although the patency of the TIPS tract did
not improve because of the partial occlusion by thrombi,
the DM-eluting stent showed a tendency to reduce the
development of pseudointimal hyperplasia in the TIPS
tract of a swine model with induced portal hypertension.
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